Prognostic Implications of AccuFFRangio-guided PCI in STEMI

Prognostic Implications of AccuFFRangio-based Functional Evaluation for Guiding Coronary Intervention for Non-IRA Stenosis in Patients With STEMI

This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis by computing the pressure in the vessel based on angiographic images. The aim of this study was to evaluate the diagnostic accuracy and prognostic implications of AccuFFRangio in patients with ST-segment elevation myocardial infarction (STEMI).

Inclusion Criteria:

• 18 Years and older
• STEMI patients with primary percutaneous coronary intervention within 24 hours with at least 1 non-IRA
• Diameter stenosis of 50%-90% by visual estimate
• Reference vessel size > 2 mm in stenotic segment by visual estimate

Exclusion Criteria:

• LVEF ≤ 40%
• eGFR < 60 mL/min
• Allergy to contrast media, adenosine
• Prior CABG